These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8250987)

  • 1. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
    Elliott MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katsikis P; Brennan FM; Walker J; Bijl H; Ghrayeb J
    Arthritis Rheum; 1993 Dec; 36(12):1681-90. PubMed ID: 8250987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
    Elliot MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katasikis P; Brennan FM; Bijl H; Ghrayeb J; Woody JN
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S92-S101. PubMed ID: 18240199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
    Elliott MJ; Maini RN; Feldmann M; Kalden JR; Antoni C; Smolen JS; Leeb B; Breedveld FC; Macfarlane JD; Bijl H
    Lancet; 1994 Oct; 344(8930):1105-10. PubMed ID: 7934491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.
    Camussi G; Lupia E
    Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.
    Elliott MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Bijl H; Woody JN
    Lancet; 1994 Oct; 344(8930):1125-7. PubMed ID: 7934495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
    Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
    Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
    Rankin EC; Choy EH; Kassimos D; Kingsley GH; Sopwith AM; Isenberg DA; Panayi GS
    Br J Rheumatol; 1995 Apr; 34(4):334-42. PubMed ID: 7788147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis.
    Moreland LW; Bucy RP; Tilden A; Pratt PW; LoBuglio AF; Khazaeli M; Everson MP; Daddona P; Ghrayeb J; Kilgarriff C
    Arthritis Rheum; 1993 Mar; 36(3):307-18. PubMed ID: 8095785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
    di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
    Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis.
    den Broeder AA; Wanten GJ; Oyen WJ; Naber T; van Riel PL; Barrera P
    J Rheumatol; 2003 Feb; 30(2):232-7. PubMed ID: 12563673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.